Inactivated Sendai virus strain Tianjin, a novel genotype of Sendai virus, inhibits growth of murine colon carcinoma through inducing immune responses and apoptosis
© Shi et al.; licensee BioMed Central Ltd. 2013
Received: 18 June 2013
Accepted: 2 September 2013
Published: 5 September 2013
Ultraviolet-inactivated, replication-defective Sendai virus particles (Z strain) have displayed antitumor effect through enhancing the immune responses or inducing apoptosis in a variety of carcinomas. Sendai virus strain Tianjin was isolated from the lungs of marmoset and proved to be a novel genotype of Sendai virus. In this study, we explored the antitumor effect and its mechanism of ultraviolet-inactivated, replication-defective Sendai virus strain Tianjin (UV-Tianjin) in mice bearing CT26 colon carcinoma.
Three injections of UV-Tianjin were delivered into CT26 tumors growing on the back of BALB/c mice. Tumor size was measured in a blinded manner and survival rate of mice was calculated. In order to make clear antitumor mechanism of UV-Tianjin, the maturation and interleukin-6 (IL-6) release from murine myeloid dendritic cells (DCs) was examined by flow cytometry or ELISA assay after induced by UV-Tianjin and compared with those of live virus. Moreover, real-time RT-PCR and immunohistochemistry was performed to identify whether UV-Tianjin could induce infiltration of DCs, CD4+ and CD8+ T cells into tumors. The TUNEL assay was done to observe the apoptosis of CT26 tumor cells after UV-Tianjin injection.
In animal model, UV-Tianjin could obviously inhibit the growth of CT26 tumors and prolong the survival of the tumor-bearing mice compared with control group (P < 0.01). In vitro murine DCs stimulated by UV-Tianjin underwent dose-dependent maturation, similar to that elicited by live virus. And the secretion amount of IL-6 from DCs induced by UV-Tianjin was a little lower than that released in the presence of live virus. Real-time RT-PCR and immunohistochemistry revealed that UV-Tianjin induced a remarkable infiltration of DCs, CD4+ and CD8+ T cells into tumors. The TUNEL assay showed that the apoptosis index of tumor tissues injected with UV-Tianjin was significantly higher than that of control group (P < 0.01).
Our results have demonstrated that UV-Tianjin alone could inhibit the growth of CT26 tumor in mice through enhancing host antitumor immunity and inducing apoptosis of tumor cells. Therefore, UV-Tianjin shows its prospect as a novel drug for carcinoma therapy.
Cancer has been one of the most serious diseases threatening to human health. Although the mortality of cancer patients has improved by operation, chemotherapy and radiotherapy, some advanced or metastatic tumors remain refractory to conventional treatment. Therefore, novel therapeutic approaches are urgently required to treat refractory tumors.
It is known for several decades that some viruses may be able to eradicate tumors. For example, adenovirus vector containing P53 gene has passed through clinical trials in many countries and proved to have therapeutic effects on various tumors[1, 2]. Moreover, a variety of live viruses such as mumps virus, measles virus, Newcastle disease virus (NDV), reovirus and vesicular stomatitis virus (VSV) have been used for cancer treatment due to their ability of killing tumor cells selectively[3–7]. Sendai virus (SeV; also known as hemagglutinating virus of Japan, HVJ) is a member of the genus Respirovirus within the family Paramyxoviridae. It usually causes outbreaks of lethal pneumonia in mouse colonies, the natural host, but is thought to be nonpathogenic to humans. UV-inactivated Sendai virus (called HVJ-envelope, HVJ-E) is unable to replicate in cells because the genome is destroyed by UV irradiation, but conserves the complete structure of the live HVJ envelope containing F, HN, and M proteins. Therefore, HVJ-E is safe and has been applied to an anticancer vaccine strategy[9, 10]. Recent studies have demonstrated that HVJ-E (Z strain) has an extensive antitumor role and could eradicate or inhibit the growth of various tumors, including colon carcinoma, renal carcinoma, prostate cancer, malignant glioma, and melanoma through inducing antitumor immunity or tumor cell apoptosis[11–15]. However, the detailed mechanism of the antitumor activity of HVJ-E is not fully understood.
Sendai virus strain Tianjin (GenBank: EF679198.1) was isolated from the lungs of marmoset with respiratory infection in 1999. Phylogenetic analysis based on complete sequence has proved that Tianjin strain was a novel genotype of Sendai virus. Our previous study has shown that non-replicating Tianjin strain could enhance the immune response through inducing the production of IFN-α, IL-6 and TNF-α in vivo. This study was designed to demonstrate that UV-inactivated Tianjin strain alone may suppress colon carcinoma growing in mice through inducing not only immune response but also tumor cell apoptosis, which may be useful in developing viral therapeutics for cancer.
Materials and methods
Cell lines and mice
The CT26 murine colon carcinoma cell line was purchased from Cell Bank of Chinese Academy of Science (Shanghai, China). The cell line was maintained in RPMI 1640 supplemented with 10% FCS (Hyclone, Beijing, China), 100 U/ml penicillin and 100 U/ml streptomycin under a humidified atmosphere containing 5% CO2 at 37°C. Six-week-old, female BALB/c mice purchased from Beijing HFK Bioscience Co., Ltd. (Beijing, China), were maintained in a temperature-controlled and pathogen-free room. All animals were handled according to the approved protocols and the guidelines of the Animal Committee of Tianjin Medical University.
Reagents and antibodies
Recombinant mouse IL-4 and GM-CSF were purchased from PeproTech Inc. (Suzhou, China). PE anti-mouse CD11c, FITC anti-mouse CD40, CD80, CD86 antibodies, PE Armenian Hamster IgG Isotype Ctrl, FITC Rat IgG2α, κ Isotype Ctrl, FITC Armenian Hamster IgG Isotype Ctrl were purchased from BioLegend (Beijing, China). Mouse IL-6 ELISA kit was obtained from RayBiotech (Guangzhou, China). Anti-CD11c antibody was purchased from Abcam Ltd (Hong Kong, China). Anti-CD4 antibody was purchased from R&D Systems China Co. Ltd. (Shanghai, China). Anti-CD8α antibody was from Santa Cruz Biotechnology Inc. (Beijing, China). TUNEL apoptosis assay kit was purchased from Roche Applied Science (Hong Kong, China).
Preparation of live Tianjin strain and UV-inactivated Tianjin strain
Tianjin strain (GenBank: EF679198.1) was preserved in our laboratory and propagated in the chorioallantoic fluid of 10-day-old embryonated chicken eggs, after which it was purified by centrifugation and inactivated by UV irradiation (99 mJ/cm2), as previously described. Inactivated virus is unable to replicate because the genome is destroyed by UV irradiation, but its capacity for viral fusion remains intact.
Preparation and culture of dendritic cells
Dendritic cells (DCs) were generated from the bone marrow precursors of BALB/c mice as described in reference. In brief, bone marrow of the tibia and femur was flushed with culture medium and treated with RBC lysis buffer for 5 min, washed twice with PBS, then cultured in complete RPMI 1640 medium supplemented with 20 ng/ml recombinant mouse GM-CSF and 20 ng/ml recombinant mouse IL-4. Half of the medium was replaced at day 2 and 4. At day 6, the suspended and loosely adherent cells were collected and CD11c molecule specific for DC was analyzed by flow cytometry. These cells were used in subsequent experiments as immature dendritic cells.
Flow cytometric analysis
Immature murine DCs (1 × 106 cells/ml) were placed in 6‒well plates and cultured with different doses of UV-inactivated Tianjin strain or live virus for 48 h. Then the DCs were incubated with anti‒mouse CD40, CD80, and CD86 antibodies, respectively. The stained cells were then analyzed with the BD FACSCalibur system and CellQuest software (BD Biosciences).
Immature murine DCs (1 × 106 cells/ml) were cultured in 96‒well plates and then different doses of UV-inactivated Tianjin strain or live virus were added to the culture medium. After 48 h, supernatants of DCs cultures were harvested. Murine IL‒6 in harvested supernatants was measured using ELISA kits according to the manufacturer’s instruction. Supplied standards were used to generate standard curves.
In vivo antitumor effect
CT-26 cells were enzymatically detached from culture flasks and counted. 5 × 106 CT26 cells were resuspended in 100 μl PBS and injected into the subcutaneous space on the back of BALB/c mice (day 0). When tumors reached 5 mm in diameter, the mice were randomly divided into two groups (n = 10 per group). One group served as control and received one intratumoral administration of 100 μl saline. The other group was intratumorally administered with UV-Tianjin, once at a dose of 5 × 108 in 100 μl saline on days 4, 8 and 12. Tumor size was measured in a blinded manner with slide calipers every other day, and survival of the animals was monitored. Tumor volume was calculated by using the following formula: tumor volume (mm3) = length × (width)2/2.
Quantitative real-time RT-PCR
Sequences of primers used in the real-time PCR amplifications
Immunohistochemical analysis of tumor tissue
Tumor tissues were harvested at 48 h after UV-Tianjin or saline injections for three successive days. All tumor tissues were fixed in 10% neutral buffered formalin and embedded in paraffin. Thin sections were stained with specific antibodies in combination with secondary antibodies according to the manufacturer’s instruction. The presence of brown granules on the surface of cells was defined as positive cell. The number of positive cells per section was counted in 10 random high-power microscopic fields (×400), and the percentage of positive cells (positive cells/total cells × 100%) was calculated. Three discontinuous sections were selected from every specimen and those indexes were averaged. The final results were expressed as percentage mean ± standard deviation (SD).
In situ detection of apoptotic cells in tumor tissue
At 48 h after three successive injections of UV-Tianjin or saline, tumor tissues were taken out from the mice. All tumor tissues were fixed in 10% neutral buffered formalin and embedded in paraffin. Analysis of apoptotic cells was performed by TUNEL apoptosis assay kit following the manufacturer’s direction. Images of the sections were taken by a fluorescence microscope (Olympus, Japan). Apoptotic index was calculated by dividing the number of TUNEL-positive cells by the total number of cells in the field.
All data were expressed as means ± SD and analyzed by one way ANOVA test with Fisher’s adjustment, except for animal survival. Survival was analyzed with the Kaplan-Meier method and the log-rank test. A probability value of P < 0.05 was considered statistically significant.
UV-Tianjin inhibited the growth of CT26 tumors and prolonged the survival of the treated mice
UV-Tianjin induced maturation and IL-6 release from murine dendritic cells
UV-Tianjin promoted dendritic cell and T-cell recruitment to tumor beds
UV-Tianjin induced the apoptosis of CT26 tumors in mice
Viral antitumor effect involves in many kinds of modes including directly killing the tumor cells, inducing tumor cells apoptosis and stimulating the immune response of host. Previous studies have shown that UV-inactivated, replication-defective Sendai virus particles (HVJ-E) could induce antitumor immunity through both the activation of CTL and natural killer (NK) cells and the suppression of regulatory T cells[11, 12]. Furthermore, HVJ-E could also induce cancer-selective apoptosis via the upregulation of TRAIL and Noxa downstream of the RIG-I/MAVS pathway.
Sendai virus strain Tianjin is a novel genotype of Sendai virus. In this study, we applied UV-inactivated, replication-defective Tianjin strain (UV-Tianjin) on a mouse model of CT26 colon carcinoma. As expected, UV-Tianjin markedly inhibited the growth of CT26 tumors and significantly prolonged the survival of the treated mice. UV-Tianjin is unable to replicate in cells because the genome is destroyed by UV irradiation. Moreover, our results showed that UV-Tianjin was non-toxic to murine CT26 cancer cell lines (Figure 1D). Therefore, the mechanism of antitumor activity for UV-Tianjin was probably not associated with direct UV-Tianjin cytotoxicity.
DCs are potent antigen presenting cells (APCs) that play a crucial role in regulating the adaptive immune response. DCs process and present antigens to activate both CD4+ and CD8+ T cells. Thus activation of tumor antigen-specific CD8+ CTL and CD4+ T helper cells generates antitumor immune response. In addition, mature DCs can express high levels of costimulatory molecules CD40, CD80 as well as CD86 and secret IL-6 and other Thl type cytokines which induce Thl cell immunity. Recently, the application of DCs in immunotherapy of tumor has become a research focus in the field of initiative specific immunotherapy of tumor[22, 23]. In the present study, we examined whether UV-Tianjin could activate DCs and induce tumor-specific immunity. We found that murine DCs underwent dose-dependent maturation by UV-Tianjin and the amount of IL-6 released from DCs was slightly diminished after UV-Tianjin stimulation as compared to live virus in vitro. Furthermore, DCs and effector T-cell recruitment to tumors after UV-Tianjin treatment was suggested from the significant increase of CD11c, CD4, and CD8 mRNA expression. Remarkable infiltrations of DCs and CD4+ and CD8+ T cells into UV-Tianjin-treated tumors were also confirmed in immunohistochemical studies. At present, the precise molecular and cellular mechanisms of activation of DCs by SeV are not well-understood. HVJ-E is known to induce maturation of dendritic cells in a Toll-like receptor-independent manner. In addition, a recent report indicated that HVJ-E could induce cytotoxic T cells against cancers and inhibit regulatory T cells by IL-6 expression in dendritic cells. These facts support the induction of anticancer immunity in colon carcinoma by UV-Tianjin treatment.
Apoptosis is ubiquitous in the majority of tumor cells, and is important in the genesis and progression of tumors. Previous studies have demonstrated that some viruses typically inhibit tumors by inducing apoptosis of sensitive tumor cells[20, 25, 26]. In our study, we also performed TUNEL assay to observe whether cell apoptosis was responsible for the antitumor effect of UV-Tianjin in vivo. Results showed that the apoptotic index of treatment group was significantly higher than that of control group. As far as we know, the molecular mechanism of HVJ-E–induced apoptosis in cancer cells has not been fully investigated. Recent data suggested that TNF-related apoptosis-inducing ligand (TRAIL) and Noxa represented promising target molecules for cancer cell-selective apoptosis when the retinoic acid–inducible gene I/mitochondrial antiviral signaling protein (RIG-I/MAVS) signaling pathway was activated. In view of the lack of replicative ability and non-toxicity to cultured CT26 cells of UV-Tianjin, we hypothesized that the possible mechanism of UV-Tianjin–induced apoptosis might be that UV-Tianjin RNA fragments are recognized by RIG-I and then the activation of the RIG-I/MAVS pathway triggers cancer cell-selective apoptosis. Further study is required to provide more proof.
Taking all these results together we demonstrated that UV-Tianjin alone had antitumor activity against colon carcinoma. Mechanistically, not only antitumor immune response through DCs and T cells but also tumor cell apoptosis was responsible for this antitumor effect. But the detailed mechanism requires to be cleared. To our knowledge, for the first time we reported the growth inhibitory effect of UV-Tianjin on colon carcinoma by inducing antitumor immune response and cell apoptosis. UV-Tianjin may offer important contributions for the development of a novel drug to prevent and cure human cancers including colon carcinoma in the future.
This work was supported by National Natural Science Foundation grants to LS (No. 81172168 and No.30900736).
- Liu C, Sun B, An N, Tan W, Cao L, Luo X, Yu Y, Feng F, Li B, Wu M, Su C, Jiang X: Inhibitory effect of Survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer. Mol Oncol. 2011, 5: 545-554. 10.1016/j.molonc.2011.10.001.View ArticlePubMedGoogle Scholar
- Pataer A, Fanale MA, Roth JA, Swisher SG, Hunt KK: Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53. Cancer Gene Ther. 2006, 13: 806-814. 10.1038/sj.cgt.7700960.View ArticlePubMedGoogle Scholar
- Studebaker AW, Hutzen B, Pierson CR, Russell SJ, Galanis E, Raffel C: Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid-disseminated medulloblastoma. Neuro Oncol. 2012, 14: 459-470. 10.1093/neuonc/nor231.PubMed CentralView ArticlePubMedGoogle Scholar
- Myers R, Greiner S, Harvey M, Soeffker D, Frenzke M, Abraham K, Shaw A, Rozenblatt S, Federspiel MJ, Russell SJ, Peng KW: Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. Cancer Gene Ther. 2005, 12: 593-599. 10.1038/sj.cgt.7700823.View ArticlePubMedGoogle Scholar
- Kumar R, Tiwari AK, Chaturvedi U, Kumar GR, Sahoo AP, Rajmani RS, Saxena L, Saxena S, Tiwari S, Kumar S: Velogenic newcastle disease virus as an oncolytic virotherapeutics: in vitro characterization. Appl Biochem Biotechnol. 2012, 167: 2005-2022. 10.1007/s12010-012-9700-1.View ArticlePubMedGoogle Scholar
- Heinemann L, Simpson GR, Boxall A, Kottke T, Relph KL, Vile R, Melcher A, Prestwich R, Harrington KJ, Morgan R, Pandha HS: Synergistic effects of oncolyticreovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer. 2011, 11: 221-10.1186/1471-2407-11-221.PubMed CentralView ArticlePubMedGoogle Scholar
- Murphy AM, Besmer DM, Moerdyk-Schauwecker M, Moestl N, Ornelles DA, Mukherjee P, Grdzelishvili VZ: Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J Virol. 2012, 86: 3073-3087. 10.1128/JVI.05640-11.PubMed CentralView ArticlePubMedGoogle Scholar
- Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, Nakamura H, Morishita R, Kotani H: Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther. 2002, 6: 219-226. 10.1006/mthe.2002.0647.View ArticlePubMedGoogle Scholar
- Hiraoka K, Yamamoto S, Otsuru S, Nakai S, Tamai K, Morishita R, Ogihara T, Kaneda Y: Enhanced tumor-specific long-term immunity of hemagglutinating virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. J Immunol. 2004, 173: 4297-4307.View ArticlePubMedGoogle Scholar
- Yamano T, Kaneda Y, Huang S, Hiramatsu SH, Hoon DS: Enhancement of immunity by a DNA melanomavaccine against TRP2 with CCL21 as an adjuvant. Mol Ther. 2006, 13: 194-202. 10.1016/j.ymthe.2005.05.018.View ArticlePubMedGoogle Scholar
- Kurooka M, Kaneda Y: Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res. 2007, 67: 227-236. 10.1158/0008-5472.CAN-06-1615.View ArticlePubMedGoogle Scholar
- Fujihara A, Kurooka M, Miki T, Kaneda Y: Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol Immunother. 2008, 57: 73-84. 10.1007/s00262-007-0351-y.View ArticlePubMedGoogle Scholar
- Kawaguchi Y, Miyamoto Y, Inoue T, Kaneda Y: Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Int J Cancer. 2009, 124: 2478-2487. 10.1002/ijc.24234.View ArticlePubMedGoogle Scholar
- Tanaka M, Shimbo T, Kikuchi Y, Matsuda M, Kaneda Y: Sterile alpha motif containing domain 9 is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon. Int J Cancer. 2010, 126: 1982-1991.View ArticlePubMedGoogle Scholar
- Zhang Q, Yuan WF, Zhai GQ, Zhu SY, Xue ZF, Zhu HF, Xu XM: Inactivated Sendai virus suppresses murine melanoma growth by inducing host immune responses and down-regulating β-catenin expression. Biomed Environ Sci. 2012, 25: 509-516.PubMedGoogle Scholar
- Shi LY, Li M, Yuan LJ, Wang Q, Li XM: A new paramyxovirus, Tianjin strain, isolated from common cotton-eared marmoset: genome characterization and structural protein sequences analysis. Arch Virol. 2008, 153: 1715-1723. 10.1007/s00705-008-0184-9.View ArticlePubMedGoogle Scholar
- Zhou HJ, Zhang J, Chen ZY, Wang F, Li XM: Study on defective interfering particles of Paramyxovirus, Tianjin strain enhanced the immune response of the mice. Chin J Microbiol Immunol. 2010, 30: 1063-1067.Google Scholar
- Kato T, Ueda Y, Kinoh H, Yoneyama Y, Matsunaga A, Komaru A, Harada Y, Suzuki H, Komiya A, Shibata S, Hasegawa M, Hayashi H, Ichikawa T, Yonemitsu Y: RIG-I helicase-independent pathway in sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6.3 prostate cancer. Neoplasia. 2010, 12: 906-914.PubMed CentralView ArticlePubMedGoogle Scholar
- Faiao Flores F, Coelho PR, Toledo Arruda Neto JD, Maria Engler SS, Tiago M, Capelozzi VL, Giorgi RR, Maria DA: Apoptosis through Bcl-2/Bax and cleaved caspase up-regulation in melanoma treated by boron neutron capture therapy. PLoS One. 2013, 8: e59639-10.1371/journal.pone.0059639.PubMed CentralView ArticlePubMedGoogle Scholar
- Matsushima-Miyagi T, Hatano K, Nomura M, Li-Wen L, Nishikawa T, Saga K, Shimbo T, Kaneda Y: TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles. Clin Cancer Res. 2012, 18: 6271-6283. 10.1158/1078-0432.CCR-12-1595.View ArticlePubMedGoogle Scholar
- Lopez CB, Moltedo B, Alexopoulou L, Flavell RA, Moran TM: TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA virus. J Immunol. 2004, 173: 6882-6889.View ArticlePubMedGoogle Scholar
- Kobukai S, Kremers GJ, Cobb JG, Baheza R, Xie J, Kuley A, Zhu M, Pham W: Induction of antitumor immunity by dendritic cells loaded with membrane-translocating mucin 1 Peptide antigen. Transl Oncol. 2011, 4: 1-8. 10.1007/s12178-010-9068-1.PubMed CentralView ArticlePubMedGoogle Scholar
- Suzuki T, Oo Chang M, Kitajima M, Takaku H: Induction of antitumor immunity against mouse carcinoma by baculovirus-infected dendritic cells. Cell Mol Immunol. 2010, 7: 440-446. 10.1038/cmi.2010.48.PubMed CentralView ArticlePubMedGoogle Scholar
- Ito T, Amakawa R, Inaba M, Hori T, Ota M, Nakamura K, Takebayashi M, Miyaji M, Yoshimura T, Inaba K, Fukuhara S: Plasmacytoid dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs. J Immunol. 2004, 172: 4253-4259.View ArticlePubMedGoogle Scholar
- Zhao D, Chen P, Yang H, Wu Y, Zeng X, Zhao Y, Wen Y, Zhao X, Liu X, Wei Y, Li Y: Live attenuated measles virus vaccine induces apoptosis and promotes tumor regression in lung cancer. Oncol Rep. 2013, 29: 199-204.PubMedGoogle Scholar
- Thirukkumaran CM, Shi ZQ, Luider J, Kopciuk K, Gao H, Bahlis N, Neri P, Pho M, Stewart D, Mansoor A, Morris DG: Reovirus as a viable therapeutic option for the treatment of multiple myeloma. Clin Cancer Res. 2012, 18: 4962-4972. 10.1158/1078-0432.CCR-11-3085.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.